ClinicalTrials.gg
CompletedNCT03675737Updated Feb 27, 2026Results posted

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

A Phase 3 interventional study of Pembrolizumab and Cisplatin in Stomach Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 215 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know · 13 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,579
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 41 studies testing pembrolizumab in Stomach Neoplasms — 7 open to participants now, 13 under way, 1 of them phase 3. pembrolizumab · Stomach Neoplasms.

Enrollment
Largest of 41
1,579 · median 41
Started
2018
with 7 others
Phase 3
10 of 41
1 open now
Registered
21st of 41
by date
Lead sponsor
12 of 41
Merck Sharp & Dohme LLC

Among the 41 studies testing pembrolizumab in Stomach Neoplasms, this one has the largest enrollment, is one of 8 that started in 2018, is one of 10 in phase 3, and was the 21st registered.

Stomach Neoplasms

3,406 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

7 of the 41 studies testing pembrolizumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing pembrolizumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen]) versus placebo in combination with chemotherapy (FP or CAPOX regimens) in the treatment of human epidermal growth factor receptor 2 (HER2) negative advanced gastric or GEJ adenocarcinoma in adult participants.

The primary hypotheses of this study are that pembrolizumab plus chemotherapy is superior to placebo plus chemotherapy in terms of overall survival (OS).

Once a participant has achieved the study objective or the study has ended, the participant will be discontinued from this study and enrolled in an extension study (Keynote 587; NCT03486873) to continue protocol-defined assessments and treatment.

03

Conditions studied

  • Stomach Neoplasms

Browse trials for

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)
  • programmed cell death ligand 2 (PD-L2, PDL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed diagnosis of locally advanced unresectable or gastric or gastroesophageal junction (GEJ) adenocarcinoma with known programmed cell death ligand 1 () expression status
  • Has human epidermal growth factor receptor 2 () negative cancer
  • Male participants must agree to use during the treatment period and through 95 days after the last dose of chemotherapy, refrain from donating sperm, and be abstinent from heterosexual intercourse, as their preferred and usual lifestyle, and agree to remain abstinent or must agree to use contraception per study protocol unless confirmed to be azoospermic during this period
  • Female participants who are not pregnant, not breastfeeding, and at least one of the following conditions applies: not a woman of (WOCBP) OR is a WOCBP who agrees to use contraception or be abstinent from heterosexual intercourse, as their preferred and usual lifestyle, during the treatment period and through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is last, and agrees not to donate eggs to others or freeze/store for her own use for the purpose of reproduction during this period
  • Has per version 1.1 (RECIST 1.1) as assessed by investigator assessment
  • Has provided sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
  • Has provided tumor tissue sample deemed adequate for PD-L1 biomarker analysis
  • Has provided tumor tissue sample for microsatellite instability (MSI) biomarker analysis
  • Has an (ECOG) performance status of 0 or 1 within 3 days prior to the start of study intervention
  • Has adequate organ function as demonstrated by laboratory testing within 10 days prior to the start of study treatment

Exclusion criteria

Exclusion Criteria

  • Has squamous cell or undifferentiated gastric cancer
  • Has had major surgery, open , or significant traumatic injury within 28 days prior to randomization, anticipation of the need for major surgery during the course of study intervention, or has not recovered adequately from the toxicity and/or complications from previous surgery
  • Has preexisting peripheral neuropathy >Grade 1
  • Is a who has a positive urine pregnancy test within 24 hours for urine or within 72 hours for serum prior to randomization or treatment allocation
  • Has had previous therapy for locally advanced, unresectable or gastric/GEJ cancer. Participants may have received prior and/or adjuvant therapy as long as it was completed ≥6 months prior to randomization
  • Has received prior therapy with an anti-programmed cell death (PD)-1, or anti-programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX- 40, CD137)
  • Has received prior systemic anticancer therapy including agents within 4 weeks prior to randomization or has not recovered from all adverse events (AEs) due to any previous therapies to ≤Grade 1 or baseline
  • Has received prior radiotherapy within 2 weeks prior to study start or has not recovered from all previous radiation-related toxicities, required , and have not had radiation pneumonitis. A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease
  • Has received a live or within 30 days prior to the first dose of study treatment
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of therapy within 7 days prior to the first dose of study treatment
  • Has a known additional that is progressing or has required active treatment within the past 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
  • Has known active and/or carcinomatous meningitis
  • Has severe (≥Grade 3) to pembrolizumab and/or any of its
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection
  • Has a known history of (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as Hepatitis C virus [HCV] ribonucleic acid [RNA] detected qualitatively) infection
  • Has a known history of active tuberculosis
  • Has hypokalemia (serum potassium less than the lower limit of normal)
  • Has hypomagnesemia (serum magnesium less than the lower limit of normal)
  • Has hypocalcemia (serum calcium less than the lower limit of normal)
  • Has a history or current evidence of any condition (eg, known deficiency of the enzyme dihydropyrimidine dehydrogenase), therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is last
  • Has had an allogenic tissue/solid organ transplant
  • Has a known severe hypersensitivity (≥ Grade 3) to any of the study chemotherapy agents (including, but not limited to, infusional 5-fluorouracil or oral capecitabine) and/or to any of their excipients
  • For participants taking cisplatin: has Grade ≥2 audiometric hearing loss
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,579 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Chemotherapy (FP or CAPOX regimen)

    Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m\^2/day via continuous IV infusion on Days 1 to 5 Q3W (FP regimen) OR oxaliplatin 130 mg/m\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\^2 orally twice a day (BID) on Days 1 to 14 Q3W (CAPOX regimen). Participants who complete up to 35 administrations of pembrolizumab (approximately 2 years) or achieve a complete response (CR) but experience progression of disease (PD), can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).

    Biological: Pembrolizumab · Drug: Cisplatin · Drug: 5-fluorouracil · Drug: oxaliplatin · Drug: capecitabine

  • Active comparator
    Placebo + Chemotherapy (FP or CAPOX regimen)

    Participants receive placebo on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m\^2 IV on Day 1 Q3W and 5FU 800 mg/m\^2/day via continuous IV infusion on Days 1 to 5 Q3W (FP regimen) OR oxaliplatin 130 mg/m\^2 IV on Day 1 Q3W + capecitabine 1000 mg/m\^2 orally BID on Days 1 to 14 Q3W (CAPOX regimen).

    Drug: Cisplatin · Drug: 5-fluorouracil · Drug: oxaliplatin · Drug: capecitabine · Drug: Placebo for Pembrolizumab

Interventions

  • BiologicalPembrolizumab

    Administered as an IV infusion on Day 1 Q3W

    Also known as: KEYTRUDA®, MK-3475

  • Administered as an IV infusion on Day 1 Q3W

    Also known as: PLATINOL®

  • DrugFluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered as a continuous IV infusion on Days 1-5 Q3W

    Also known as: ADRUCIL®, 5FU

  • Administered as an IV infusion on Day 1 Q3W

    Also known as: ELOXATIN®

  • Administered orally BID on Days 1 to 14 Q3W

    Also known as: XELODA®

  • DrugPlacebo for Pembrolizumab

    Administered as an IV infusion on Day 1 Q3W

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in All Participants

    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to 45.9 months

  2. Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to 45.9 months

  3. Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to 45.9 months

Secondary outcomes

  1. Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to 49.5 months

  2. Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to 49.5 months

  3. Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to 49.5 months

  4. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants

    ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR.

    Time frame: Up to 49.5 months

  5. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

    ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR.

    Time frame: Up to 49.5 months

  6. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

    ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR.

    Time frame: Up to 49.5 months

  7. Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants

    DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to 49.5 months

  8. Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

    DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to 49.5 months

  9. Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

    DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data.

    Time frame: Up to 49.5 months

  10. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence, in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE is presented.

    Time frame: Up to approximately 49.3 months

  11. Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented.

    Time frame: Up to approximately 46.3 months

07

Results

Posted Oct 12, 2023

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Started790789
Treated785787
Received pembrolizumab second course120
Completed00
Not completed790789
Withdrew: Death685726
Withdrew: Lost to follow-up24
Withdrew: Withdrawal by subject1513
Withdrew: Sponsor decision8846

Outcome measures

PrimaryOverall Survival (OS) in All Participants

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to 45.9 months
Reported as:
Median · Months
Overall Survival (OS) in All Participants
MonthsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Overall Survival (OS) in All Participants12.9 (11.9 to 14.0)11.5 (10.6 to 12.1)
Statistical analysis
  • Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen) · Log Rank · p = <0.0001 (One-sided p-value based on log-rank test stratified by geographic region, Programmed Cell Death Ligand 1 (PD-L1) status (Combined Positive Score \[CPS\] \<1 versus CPS ≥1), and chemotherapy regimen with small strata collapsed.) · Hazard ratio (hr): 0.78 · 95% CI 0.70 to 0.87Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region, PD-L1 status (CPS \<1 versus CPS ≥1), and chemotherapy regimen with small strata collapsed.
PrimaryOverall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to 45.9 months
Reported as:
Median · Months
Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1
MonthsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥113.0 (11.6 to 14.2)11.4 (10.5 to 12.0)
Statistical analysis
  • Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen) · Log Rank · p = <0.0001 (One-sided p-value based on log-rank test stratified by geographic region and chemotherapy regimen with small strata collapsed.) · Hazard ratio (hr): 0.74 · 95% CI 0.65 to 0.84Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region and chemotherapy regimen with small strata collapsed.
PrimaryOverall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to 45.9 months
Reported as:
Median · Months
Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
MonthsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1015.7 (13.8 to 19.3)11.8 (10.3 to 12.7)
Statistical analysis
  • Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen) · Log Rank · p = <0.0001 (One-sided p-value based on log-rank test stratified by geographic region and chemotherapy regimen with small strata collapsed.) · Hazard ratio (hr): 0.65 · 95% CI 0.53 to 0.79Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region and chemotherapy regimen with small strata collapsed.
SecondaryProgression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to 49.5 months
Reported as:
Median · Months
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants
MonthsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants6.9 (6.3 to 7.2)5.6 (5.5 to 5.7)
Statistical analysis
  • Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen) · Log Rank · p = <0.0001 (One-sided p-value based on log-rank test stratified by geographic region, Programmed Cell Death Ligand 1 (PD-L1) status (Combined Positive Score \[CPS\] \<1 versus CPS ≥1), and chemotherapy regimen with small strata collapsed.) · Hazard ratio (hr): 0.76 · 95% CI 0.67 to 0.85Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region, PD-L1 status (CPS \<1 versus CPS ≥1), and chemotherapy regimen with small strata collapsed.
SecondaryProgression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to 49.5 months
Reported as:
Median · Months
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1
MonthsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥16.9 (6.0 to 7.2)5.6 (5.4 to 5.7)
Statistical analysis
  • Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen) · Log Rank · p = <0.0001 (One-sided p-value based on log-rank test stratified by geographic region and chemotherapy regimen with small strata collapsed.) · Hazard ratio (hr): 0.72 · 95% CI 0.63 to 0.82Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region and chemotherapy regimen with small strata collapsed.
SecondaryProgression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to 49.5 months
Reported as:
Median · Months
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
MonthsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥108.1 (6.8 to 8.5)5.6 (5.4 to 6.7)
Statistical analysis
  • Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen) · Log Rank · p = <0.0001 (One-sided p-value based on log-rank test stratified by geographic region and chemotherapy regimen with small strata collapsed.) · Hazard ratio (hr): 0.62 · 95% CI 0.51 to 0.76Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by geographic region and chemotherapy regimen with small strata collapsed.
SecondaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants

ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR.

Time frame:
Up to 49.5 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants
Percentage of ParticipantsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants51.3 (47.7 to 54.8)42.0 (38.5 to 45.5)
Statistical analysis
  • Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen) · Miettinen & Nurminen method · p = 0.00009 (One-sided p-value based on Miettinen \& Nurminen method stratified by geographic region, Programmed Cell Death Ligand 1 (PD-L1) status (Combined Positive Score \[CPS\] \<1 versus CPS ≥1), and chemotherapy regimen with small strata collapsed.) · Difference in percentage: 9.3 · 95% CI 4.4 to 14.1Based on Miettinen \& Nurminen method stratified by geographic region, PD-L1 status (CPS \<1 versus CPS ≥1), and chemotherapy regimen with small strata collapsed.
SecondaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR.

Time frame:
Up to 49.5 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1
Percentage of ParticipantsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥152.1 (48.1 to 56.1)42.6 (38.7 to 46.6)
Statistical analysis
  • Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen) · Miettinen & Nurminen method · p = 0.00041 (One-sided p-value based on Miettinen \& Nurminen method stratified by geographic region and chemotherapy regimen with small strata collapsed.) · Difference in percentage: 9.5 · 95% CI 3.9 to 15.0Based on Miettinen \& Nurminen method stratified by geographic region and chemotherapy regimen with small strata collapsed.
SecondaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR.

Time frame:
Up to 49.5 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
Percentage of ParticipantsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1060.6 (54.6 to 66.3)43.0 (37.1 to 49.1)
Statistical analysis
  • Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen) · Miettinen & Nurminen method · p = 0.00002 (One-sided p-value based on Miettinen \& Nurminen method stratified by geographic region and chemotherapy regimen with small strata collapsed.) · Difference in percentage: 17.5 · 95% CI 9.3 to 25.5Based on Miettinen \& Nurminen method stratified by geographic region and chemotherapy regimen with small strata collapsed.
SecondaryDuration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants

DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to 49.5 months
Reported as:
Median · Months
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants
MonthsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants8.0 (7.0 to 9.7)5.7 (5.5 to 6.9)
SecondaryDuration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to 49.5 months
Reported as:
Median · Months
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1
MonthsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥18.3 (7.0 to 10.9)5.6 (5.4 to 6.9)
SecondaryDuration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data.

Time frame:
Up to 49.5 months
Reported as:
Median · Months
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
MonthsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1010.9 (8.0 to 13.8)5.8 (5.3 to 7.0)
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was defined as any untoward medical occurrence, in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE is presented.

Time frame:
Up to approximately 49.3 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Number of Participants Who Experienced an Adverse Event (AE)776771
SecondaryNumber of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented.

Time frame:
Up to approximately 46.3 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)
ParticipantsPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)
Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)267206

Adverse events

Collected over Up to approximately 49.3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)689/790 (87.2%)358/785 (45.6%)755/785 (96.2%)
Placebo + Chemotherapy (FP or CAPOX Regimen)733/789 (92.9%)317/787 (40.3%)751/787 (95.4%)
Pembrolizumab Second Course8/12 (66.7%)1/12 (8.3%)10/12 (83.3%)
Most frequent serious events
Showing 10 of 336
Most frequent serious events
EventPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)Pembrolizumab Second Course
Upper gastrointestinal haemorrhageGastrointestinal disorders9/7858/7871/12
DiarrhoeaGastrointestinal disorders32/78525/7870/12
PneumoniaInfections and infestations30/78514/7870/12
VomitingGastrointestinal disorders19/78523/7870/12
ColitisGastrointestinal disorders16/7854/7870/12
Pulmonary embolismRespiratory, thoracic and mediastinal disorders15/7856/7870/12
DysphagiaGastrointestinal disorders9/78515/7870/12
NauseaGastrointestinal disorders14/78511/7870/12
Abdominal painGastrointestinal disorders12/7859/7870/12
PyrexiaGeneral disorders12/7859/7870/12
Most frequent other events
Showing 10 of 65
Most frequent other events
EventPembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)Pembrolizumab Second Course
NauseaGastrointestinal disorders359/785359/7871/12
AnaemiaBlood and lymphatic system disorders325/785282/7873/12
DiarrhoeaGastrointestinal disorders255/785238/7872/12
VomitingGastrointestinal disorders252/785192/7871/12
Decreased appetiteMetabolism and nutrition disorders227/785217/7871/12
Platelet count decreasedInvestigations207/785187/7872/12
Neutrophil count decreasedInvestigations199/785175/7871/12
LymphopeniaBlood and lymphatic system disorders28/78516/7873/12
AstheniaGeneral disorders125/785119/7873/12
FatigueGeneral disorders195/785191/7870/12

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(Years)Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)Total
Mean59.3 ± 11.960.0 ± 11.859.6 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)Total
Female263245508
Male5275441071
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)Total
Hispanic or Latino175157332
Not Hispanic or Latino5906151205
Unknown or Not Reported251742
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)Total
American Indian or Alaska Native313667
Asian270269539
Native Hawaiian or Other Pacific Islander123
Black or African American12921
White426435861
More than one race433073
Unknown or Not Reported7815
Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) <1 and CPS ≥1 Status
Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) <1 and CPS ≥1 Status(Participants)Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)Total
CPS ≥16186171235
CPS <1172172344
Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 Status
Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 Status(Participants)Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)Total
CPS ≥10280273553
CPS <105085161024
Unknown202
Chemotherapy Regimen
Chemotherapy Regimen(Participants)Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)Total
FP Regimen108108216
CAPOX Regimen6826811363
Geographic Region
Geographic Region(Participants)Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)Placebo + Chemotherapy (FP or CAPOX Regimen)Total
Western Europe/Israel/North America/Australia201202403
Asia263262525
Rest of World326325651
08

Study locations

215 sites
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0124)
    Los Angeles, California 90095, United States
  • UC Irvine Health/Division of Hematology Oncology, Dept of Medicine ( Site 0128)
    Orange, California 92868, United States
  • University of Miami, Sylvester Comprehensive Cancer Center ( Site 0113)
    Miami, Florida 33136, United States
  • Greater Baltimore Medical Center ( Site 0102)
    Baltimore, Maryland 21204, United States
  • Minnesota Oncology Hematology, PA ( Site 8000)
    Minneapolis, Minnesota 55404, United States
  • University of Rochester ( Site 0122)
    Rochester, New York 14642, United States
  • Cancer Treatment Centers of America - Philadelphia ( Site 0112)
    Philadelphia, Pennsylvania 19124, United States
  • Allegheny General Hospital ( Site 0118)
    Pittsburgh, Pennsylvania 15212, United States
  • Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 8001)
    Roanoke, Virginia 24014, United States
  • Wenatchee Valley Clinic [Wenatchee, WA] ( Site 0116)
    Wenatchee, Washington 98801, United States
  • Instituto Medico Alexander Fleming ( Site 0307)
    Buenos Aires, Buenos Aires F.D. C1426ANZ, Argentina
  • Instituto de Investigaciones Metabolicas ( Site 0312)
    Buenos Aires, C1012AAR, Argentina
  • Fundacion Favaloro - Hospital Universitario ( Site 0302)
    Buenos Aires, C1093AAS, Argentina
  • Centro Oncologico Riojano Integral ( Site 0313)
    La Rioja, F5300COE, Argentina
  • Instituto San Marcos ( Site 0311)
    San Juan, J5400EBB, Argentina
  • Liverpool Hospital ( Site 2301)
    Liverpool, New South Wales 2170, Australia
  • Southern Medical Day Care Centre ( Site 2303)
    Wollongong, New South Wales 2500, Australia
  • Box Hill Hospital ( Site 2300)
    Box Hill, Victoria 3128, Australia
  • Instituto do Cancer do Ceara ( Site 0407)
    Fortaleza, Ceará 60430-230, Brazil
  • CIONC - Centro Integrado de Oncologia de Curitiba ( Site 0405)
    Curitiba, Paraná 80810-050, Brazil
  • Hospital de Caridade de Ijui ( Site 0402)
    Ijuí, Rio Grande do Sul 98700 000, Brazil
  • Hospital Nossa Senhora da Conceicao ( Site 0403)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • CEPON - Centro de Pesquisas Oncologicas ( Site 0400)
    Florianópolis, Santa Catarina 88034-000, Brazil
  • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0401)
    Rio de Janeiro, 20231-050, Brazil
  • IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0404)
    São Paulo, 03102-002, Brazil
  • BC Cancer - Abbotsford ( Site 0206)
    Abbotsford British Columbia, British Columbia V2S 0C2, Canada
  • Sunnybrook Research Institute ( Site 0202)
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre ( Site 0203)
    Toronto, Ontario M5G 2M9, Canada
  • McGill University Health Centre ( Site 0208)
    Montreal, Quebec H4A 3J1, Canada
  • Instituto Clinico Oncologico del Sur ( Site 0500)
    Temuco, Araucania 4810469, Chile
  • Fundacion Arturo Lopez Perez FALP ( Site 0501)
    Santiago, Region M. de Santiago 7500921, Chile
  • Sociedad Oncovida S.A. ( Site 0508)
    Santiago, Region M. de Santiago 7510032, Chile
  • Pontificia Universidad Catolica de Chile ( Site 0502)
    Santiago, Region M. de Santiago 7620002, Chile
  • Cancer Hospital Chinese Academy of Medical Sciences ( Site 2421)
    Beijing, Beijing Municipality 100021, China
  • Peking Union Medical College Hospital ( Site 2425)
    Beijing, Beijing Municipality 100730, China
  • Fujian Medical University Union Hospital ( Site 2410)
    Fuzhou, Fujian 350001, China
  • Fujian Provincial Cancer Hospital ( Site 2414)
    Fuzhou, Fujian 350014, China
  • 900 Hospital of the Joint ( Site 2418)
    Fuzhou, Fujian 350025, China
  • The First Affiliated Hospital of Xiamen University ( Site 2430)
    Xiamen, Fujian 361003, China
  • Zhongshan Hospital Xiamen University ( Site 2447)
    Xiamen, Fujian 361004, China
  • Guangdong General Hospital ( Site 2431)
    Guangzhou, Guangdong 510080, China
  • Peking University Shenzhen Hospital ( Site 2442)
    Shenzhen, Guangdong 518036, China
  • Fourth Hospital Of Hebei Medical University ( Site 2436)
    Shijiazhuang, Hebei 050011, China
  • Harbin Medical University Cancer Hospital ( Site 2401)
    Harbin, Heilongjiang 150081, China
  • Henan Cancer Hospital ( Site 2415)
    Zhengzhou, Henan 450008, China
  • Hubei Cancer Hospital ( Site 2434)
    Wuhan, Hubei 430079, China
  • Xiangya Hospital Central-South University ( Site 2419)
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital ( Site 2439)
    Changsha, Hunan 410013, China
  • Changzhou Cancer Hospital-Changzhou Fourth Peoples Hospital ( Site 2441)
    Changzhou, Jiangsu 213032, China
  • The 81st Hospital of PLA ( Site 2413)
    Nanjing, Jiangsu 210002, China
  • Jiangsu Cancer Hospital ( Site 2432)
    Nanjing, Jiangsu 210009, China
  • Yancheng First People s Hospital ( Site 2426)
    Yancheng, Jiangsu 224000, China
  • The First Affiliated Hospital of Nanchang University ( Site 2440)
    Nanchang, Jiangxi 330006, China
  • The First Hospital of Jilin University ( Site 2416)
    Changchun, Jilin 130021, China
  • The Affiliated Hospital of Qingdao University ( Site 2405)
    Qingdao, Shandong 266061, China
  • Shanghai East Hospital ( Site 2403)
    Shanghai, Shanghai Municipality 200120, China
  • Zhongshan Hospital affiliated to Fudan University ( Site 2407)
    Shanghai, Shanghai Municipality 210000, China
  • 1st Affil hosp of Med College of Xi'an Jiaotong University ( Site 2428)
    XiAn, Shanxi 710061, China
  • Cancer Hospital Affiliated to Xinjiang Medical University ( Site 2420)
    Ürümqi, Xinjiang 830001, China
  • Zhejiang Provincial People's Hospital ( Site 2446)
    Hangzhou, Zhejiang 310014, China
  • Sir Run Run Show Hospital ( Site 2427)
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital ( Site 2417)
    Hangzhou, Zhejiang 310022, China
  • Instituto Nacional de Cancerologia E.S.E ( Site 0605)
    Bogotá, Bogota D.C. 110321, Colombia
  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0608)
    Valledupar, Cesar Department 200001, Colombia
  • Oncomedica S.A. ( Site 0606)
    Montería, Departamento de Córdoba 230002, Colombia
  • Centro Medico Imbanaco de Cali S.A ( Site 0604)
    Cali, Valle del Cauca Department 760042, Colombia
  • CIMCA Centro de Investigacion y Manejo del Cancer ( Site 3001)
    San José, 10103, Costa Rica
  • Policlinico San Bosco ( Site 3002)
    San José, 10103, Costa Rica
  • ICIMED - Instituto de Investigacion en Ciencias Medicas ( Site 3000)
    San José, 10108, Costa Rica
  • FN Ostrava ( Site 3105)
    Ostrava, Moravian-Silesian Region 708 52, Czechia
  • Fakultni nemocnice Plzen ( Site 3102)
    Pilsen, Plzeň Region 304 60, Czechia
  • Masarykuv onkologicky ustav ( Site 3103)
    Brno, South Moravian 65653, Czechia
  • Nemocnice AGEL Novy Jicin a.s. ( Site 3104)
    Nový Jičín, 74101, Czechia
  • Fakultni nemocnice Olomouc ( Site 3100)
    Olomouc, 779 00, Czechia
  • Fakultni Thomayerova nemocnice ( Site 3101)
    Prague, 140 59, Czechia
  • Rigshospitalet ( Site 3202)
    Copenhagen, Capital Region 2100, Denmark
  • Aalborg University Hospital ( Site 3204)
    Aalborg, North Denmark 9000, Denmark
  • Odense Universitets Hospital ( Site 3201)
    Odense, Region Syddanmark 5000, Denmark
  • CHU de Rouen ( Site 1006)
    Rouen, Ain 76000, France
  • CHU-Jean Minjoz ( Site 1002)
    Besançon, Doubs 25030, France
  • C.H.R.U. de Brest - Hopital Morvan ( Site 1007)
    Brest, Finistere 29200, France
  • Centre Oscar Lambret ( Site 1003)
    Lille, Nord 59000, France
  • Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1004)
    Saint-Herblain, Val-de-Marne 44805, France
  • Institut Gustave Roussy ( Site 1000)
    Villejuif, Val-de-Marne 94805, France
  • CHU Hopital Saint Antoine ( Site 1001)
    Paris, 75012, France
  • SLK-Kliniken Heilbronn ( Site 1104)
    Heilbronn, Baden-Wurttemberg 74078, Germany
  • Universitaetsklinikum Leipzig ( Site 1114)
    Leipzig, Saxony 04103, Germany
  • Charite Universitaetsmedizin Berlin ( Site 1101)
    Berlin, 13353, Germany
  • Facharztzentrum Eppendorf ( Site 1121)
    Hamburg, 20249, Germany
  • Asklepios Klinik Altona ( Site 1100)
    Hamburg, 22763, Germany
  • Celan SA ( Site 0705)
    Guatemala City, 01010, Guatemala
  • Oncomedica ( Site 0702)
    Guatemala City, 01010, Guatemala
  • Grupo Angeles SA ( Site 0701)
    Guatemala City, 01015, Guatemala
  • MEDI-K CAYALA ( Site 0704)
    Guatemala City, 01016, Guatemala
  • Centro Regional de Sub Especialidades Medicas SA ( Site 0703)
    Quetzaltenango, 09001, Guatemala
  • Prince of Wales Hospital ( Site 2503)
    Hong Kong, Hong Kong
  • Princess Margaret Hospital. ( Site 2502)
    Hong Kong, Hong Kong
  • Queen Mary Hospital ( Site 2501)
    Hong Kong, Hong Kong
  • Bacs-Kiskun Megyei Korhaz ( Site 3306)
    Kecskemét, Bács-Kiskun county 6000, Hungary
  • Jasz-Nagykun-Szolnok Megyei Hetenyi Gyula Korhaz-Rendelointezet ( Site 3302)
    Szolnok, Jász-Nagykun-Szolnok 5004, Hungary

Showing the first 100 of 215 sites across 33 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rha SY, Oh DY, Yanez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernandez MG, Li J, Lowery MA, Cil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. PubMed 37875143 ↗
  • Qin S, Bai Y, Li J, Pan H, Luo S, Qu Y, Ye F, Yang L, Liu T, Li W, Chen X, Yang J, Ying J, Lin X, Zhao L, Liang X, Mao Y, Guo R, Zuo Y, Bordia S, Li S. First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study. Adv Ther. 2025 Apr;42(4):1892-1906. doi: 10.1007/s12325-024-03069-4. Epub 2025 Mar 1. PubMed 40025394 ↗
  • Wyrwicz L, Kalampoki V, Valderrama A, Young K. Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis. Immunotherapy. 2026 Feb;18(3):161-167. doi: 10.1080/1750743X.2026.2647579. Epub 2026 Apr 11. PubMed 41964430 ↗
  • Yasui H, Aizawa M, Yamaguchi K, Kawazoe A, Hara H, Tsuda M, Shoji H, Sugimoto N, Shibata N, Amagai K, Choda Y, Iwagami S, Esaki T, Kadowaki S, Shiratori S, Han S, Bordia S, Shitara K. First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study. Int J Clin Oncol. 2025 Oct;30(10):2003-2011. doi: 10.1007/s10147-025-02847-6. Epub 2025 Aug 1. PubMed 40750941 ↗
  • Tabernero J, Bang YJ, Van Cutsem E, Fuchs CS, Janjigian YY, Bhagia P, Li K, Adelberg D, Qin SK. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. Future Oncol. 2021 Aug;17(22):2847-2855. doi: 10.2217/fon-2021-0176. Epub 2021 May 12. PubMed 33975465 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Oct 2022, 46 months.

Results were first posted in Oct 2023, 1 year after primary completion.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 46 months is close to that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2018
First posted
Sep 18, 2018
StartActual
Nov 8, 2018
Primary completionActual
Oct 3, 2022
CompletionActual
Mar 3, 2025
Results first posted
Oct 12, 2023
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03675737
Responsible party
Sponsor
First posted
Sep 18, 2018
Start date
Nov 8, 2018
Primary completion
Oct 3, 2022
Completion
Mar 3, 2025
Results posted
Oct 12, 2023
Last update
Feb 27, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion